Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)

Diabetologia

Volumn 61, Issue 1, 2018, Pages 48-57

  Zinman, Bernard ^a   Marso, Steven P ^b   Poulter, Neil R ^c   Emerson, Scott S ^d   Pieber, Thomas R ^e   Pratley, Richard E ^f,g   Lange, Martin ^h   Brown Frandsen, Kirstine ^h   Moses, Alan ^h   Ocampo Francisco, Ann Marie ^h   Barner Lekdorf, Jesper ^h   Kvist, Kajsa ^h   Buse, John B ⁱ  

^a MOUNT SINAI HOSPITAL   (Canada)

^b Research Medical Center Brookside Campus   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF WASHINGTON   (United States)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f FLORIDA HOSPITAL   (United States)

^g BURNHAM INSTITUTE   (United States)

^h NOVO NORDISK A S   (Denmark)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoglycaemia; Insulin therapy; Macrovascular disease

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DEGLUDEC; INSULIN GLARGINE; ANTIDIABETIC AGENT; INSULIN;

ACUTE CORONARY SYNDROME; AGED; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG SAFETY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY ANALYSIS; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 85029546960     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4423-z     Document Type: Article

References (42)

1. Dailey G (2011) Overall mortality in diabetes mellitus: where do we stand today? Diabetes Technol Ther 13(Suppl. 1):S65–S74
2. Fidler C, Elmelund Christensen T, Gillard S (2011) Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ 14:646–655
3. Frier BM (2008) How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res Rev 24:87–92
4. Brod M, Galstyan G, Unnikrishnan AG et al (2016) Self-treated hypoglycemia in type 2 diabetes mellitus: results from the second wave of an international cross-sectional survey. Diabetes Ther 7:279–293
5. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM (2012) Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 29:682–689
6. Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J (2011) Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care 34:1164–1170
7. Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 119:351–357
8. Cha SA, Yun JS, Lim TS et al (2016) Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J 40:202–210
9. Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410–1418
10. Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK (2015) Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 38:316–322
11. Hirakawa Y, Arima H, Zoungas S et al (2014) Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial. Diabetes Care 37:2359–2365
12. Bailey TS, Bhargava A, Hans de Vries J et al (2017) Day-to-day variability of fasting self-measured plasma glucose (SMPG) correlates with risk of hypoglycemia in adults with type 1 (T1D) and type 2 diabetes (T2D). Diabetes 66(Suppl. 1):A104
13. Miller ME, Bonds DE, Gerstein HC et al (2010) The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 340:b5444
14. Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412
15. Heller SR, Bergenstal RM, White WB et al (2017) Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: the EXAMINE trial. Diabetes Obes Metab 19:664–671
16. Ceriello A, Kilpatrick ES (2013) Glycemic variability: both sides of the story. Diabetes Care 36(Suppl. 2):S272–S275
17. Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A (2013) Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract 102:86–95
18. Lin CC, Li CI, Yang SY et al (2012) Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med 125:416.e9–e18
19. Smith-Palmer J, Brändle M, Trevisan R, Orsini Federici M, Liabat S, Valentine W (2014) Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract 105:273–284
20. Haahr H, Heise T (2014) A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 53:787–800
21. Heise T, Nørskov M, Nosek L, Kaplan K, Famulla S, Haahr HL (2017) Insulin degludec: lower day-to-day and within-day variability in pharmacodynamic response compared to insulin glargine U300 in type 1 diabetes. Diabetes Obes Metab 19:1032–1039
22. Ratner RE, Gough SC, Mathieu C et al (2013) Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 15:175–184
23. Wysham C, Bhargava A, Chaykin L et al (2017) Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA 318:45–56
24. Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723–732
25. Marso SP, McGuire DK, Zinman B et al (2016) Design of DEVOTE (trial comparing cardiovascular safety of insulin degludec vs insulin glargine in patients with type 2 diabetes at high risk of cardiovascular events)—DEVOTE 1. Am Heart J 179:175–183
26. World Medical Association. Declaration of Helsinki (2013) Ethical principles for medical research involving human subjects. JAMA 310:2191–2194
27. ICH harmonised tripartite guideline: guideline for good clinical practice (2001) J Postgrad Med 47:199–203
28. Seaquist ER, Anderson J, Childs B et al (2013) Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 36:1384–1395
29. Kirkwood TBL (1979) Geometric means and measures of dispersion. Biometrics 35:908–909
30. Crenier L, Abou-Elias C, Corvilain B (2013) Glucose variability assessed by low blood glucose index is predictive of hypoglycemic events in patients with type 1 diabetes switched to pump therapy. Diabetes Care 36:2148–2153
31. Takao T, Matsuyama Y, Yanagisawa H, Kikuchi M, Kawazu S (2014) Association between HbA1c variability and mortality in patients with type 2 diabetes. J Diabetes Complications 28:494–499
32. Akrivos J, Ravona-Springer R, Schmeidler J et al (2015) Glycemic control, inflammation, and cognitive function in older patients with type 2 diabetes. Int J Geriatr Psychiatry 30:1093–1100
33. Cox DJ, Kovatchev BP, Julian DM et al (1994) Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 79:1659–1662
34. Monnier L, Wojtusciszyn A, Colette C, Owens D (2011) The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther 13:813–818
35. Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC (2004) A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: the Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med 164:1445–1450
36. Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH (2012) Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther 14:1008–1012
37. Niskanen L, Virkamäki A, Hansen JB, Saukkonen T (2009) Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract 86:e15–e18
38. Ceriello A, Esposito K, Piconi L et al (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 57:1349–1354
39. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharrón JL, Machado RA (2006) Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 5:4
40. Ceriello A, Taboga C, Tonutti L et al (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211–1218
41. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
42. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139